Project Summary/Abstract This application is being submitted to continue accrual participation in the Early Drug Development Opportunity (EDDOP). The Rogel Cancer Center first received National Cancer Institute (NCI) Cancer Center designation in 1988, and it has been a comprehensive cancer center continuously since 1991. The Rogel Cancer Center has a long, successful track record of participation in National Group clinical trial networks, including the National Clinical Trials Network (NCTN), the Pediatric Early Phase Clinical Trials Network (PEP-CTN), and the Bone Marrow Transplant Clinical Trials Network (BMT-CTN). The University of Michigan is a Lead Academic Participating Site (LAPS) in the NCTN, supporting a core staff with specialized expertise in National Group trial registrations. Although previously a part of the University of Chicago Phase II Consortium until 2016, we are not currently either a Lead Academic Organization (LAO) or and Affiliated Organization (AO) for the ETCTN. The Rogel Cancer Center is committed to contributing to high priority early phase trials through the ETCTN. Given our center’s history, and our faculty’s continued strong interest in ETCTN trials, we will be able to meet or exceed the goal to support our continued participation in the EDDOP program.